ACS患者联合应用肝素、替罗非班的有效性与安全性比较

The Comparision of The Efficacy and Security between the Treatment of Tirofiban and Heparin in ACS Patients

目的:比较依诺肝素与普通肝素分别联合替罗非班在急性冠脉综合征(ACS)应用过程中有效性与安全性。方法:连续选择ACS患者180例,随机分为依诺肝素组92例,普通肝素组88例,2组都联合应用替罗非班及常规治疗。观察2组患者治疗前后血小板总数及出血并发症,并随访1月内再发临床事件情况。结果:用药36小时前后血小板数量下降程度及用药36小时内出血并发症依诺肝素组较普通肝素组低(P<0.05);36小时、1月内再发临床事件2组对比无统计学差异(P>0.05)。结论:在应用替罗非班过程中可以用依诺肝素替代普通肝素。

Objective： Through our clinical trial, the differences that represent the efficacy and the security between the treatment of tirofiban and heparin in acute coronary syndrome（ACS） patients would be concluded by comparing the trial team and the control. Methods： There were 180 patients who were admitted continuously and diagnosed as ACS. They were dived into two groups randomly, the trial team contained 92 participants, and the other one contained 88 participants. Both of them were treated with tirofiban and traditional regimen. Additionally, enOXaparin was added in the trial group, and the unfraction heparin in the control one. The platelet accounts and the hemorrhage complication preor after treatment were documented. The patients were followed for one month to document the re-ischemic events and the mortalipy rate. Results： The trial group prescripted a better performance in the decrease of platelet account and hemorrhage complication comparing with the control one（P〈0.05） ： but there were no statistical differences in the rate of re-clinical events in 36 hours, neither were in the month（P〉0.05）. Conclusions： In the treatment of tirofiban, enOXaparin can replace the unfraction heparin.